JP2012512641A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512641A5
JP2012512641A5 JP2011541469A JP2011541469A JP2012512641A5 JP 2012512641 A5 JP2012512641 A5 JP 2012512641A5 JP 2011541469 A JP2011541469 A JP 2011541469A JP 2011541469 A JP2011541469 A JP 2011541469A JP 2012512641 A5 JP2012512641 A5 JP 2012512641A5
Authority
JP
Japan
Prior art keywords
seq
light chain
binding protein
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011541469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512641A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/067515 external-priority patent/WO2010070094A1/en
Publication of JP2012512641A publication Critical patent/JP2012512641A/ja
Publication of JP2012512641A5 publication Critical patent/JP2012512641A5/ja
Ceased legal-status Critical Current

Links

JP2011541469A 2008-12-19 2009-12-18 ミオスタチン結合タンパク質 Ceased JP2012512641A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13898008P 2008-12-19 2008-12-19
US61/138,980 2008-12-19
PCT/EP2009/067515 WO2010070094A1 (en) 2008-12-19 2009-12-18 Myostatin binding proteins

Publications (2)

Publication Number Publication Date
JP2012512641A JP2012512641A (ja) 2012-06-07
JP2012512641A5 true JP2012512641A5 (cg-RX-API-DMAC7.html) 2013-01-31

Family

ID=41786068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011541469A Ceased JP2012512641A (ja) 2008-12-19 2009-12-18 ミオスタチン結合タンパク質

Country Status (24)

Country Link
US (1) US20110256132A1 (cg-RX-API-DMAC7.html)
EP (1) EP2358753A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012512641A (cg-RX-API-DMAC7.html)
KR (1) KR20110103431A (cg-RX-API-DMAC7.html)
CN (1) CN102325793A (cg-RX-API-DMAC7.html)
AR (1) AR074777A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009329533A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922405A2 (cg-RX-API-DMAC7.html)
CA (1) CA2747062A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001503A1 (cg-RX-API-DMAC7.html)
CO (1) CO6400149A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110358A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000189A (cg-RX-API-DMAC7.html)
EA (1) EA201190018A1 (cg-RX-API-DMAC7.html)
IL (1) IL213243A0 (cg-RX-API-DMAC7.html)
MA (1) MA32980B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006611A (cg-RX-API-DMAC7.html)
NZ (1) NZ593297A (cg-RX-API-DMAC7.html)
PE (1) PE20120429A1 (cg-RX-API-DMAC7.html)
SG (1) SG172039A1 (cg-RX-API-DMAC7.html)
TW (1) TW201029662A (cg-RX-API-DMAC7.html)
UY (1) UY32341A (cg-RX-API-DMAC7.html)
WO (1) WO2010070094A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104397B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG10201604493TA (en) * 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
SG11201501741YA (en) * 2012-09-13 2015-04-29 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
EP3215175A4 (en) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
MX2017013267A (es) * 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
ES3030258T3 (en) 2015-09-15 2025-06-27 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
KR102709693B1 (ko) * 2015-12-18 2024-09-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドScholar Rock,Inc. 抗プロ/潜在型ミオスタチン抗体およびその使用方法
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
KR102680483B1 (ko) 2016-06-17 2024-07-01 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
FR3055548B1 (fr) * 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
PT3565592T (pt) * 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
HUE061656T2 (hu) 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
JP7579706B2 (ja) 2018-03-01 2024-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 体組成を変更するための方法
EP4596043A3 (en) 2018-04-06 2025-10-01 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
KR20210104744A (ko) 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
TWI836364B (zh) * 2021-04-28 2024-03-21 沛爾生技醫藥股份有限公司 慢病毒包裝系統以及使用其以提高宿主細胞之慢病毒產量的方法
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
US20240389949A1 (en) * 2021-10-20 2024-11-28 Arizona Board Of Regents On Behalf Of Arizona State University Systems, methods, and apparatuses for implementing cloud-based health, nutritional, and body composition analysis
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
IL131131A0 (en) 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Her2に対する結合親和性を有するポリペプチド
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
ATE557042T1 (de) 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
CA2573745A1 (en) 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
GB0425555D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
AU2006239860B2 (en) * 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
ATE539152T1 (de) 2005-05-20 2012-01-15 Glaxosmithkline Llc Neue verfahren
MX2008002367A (es) * 2005-08-19 2008-03-18 Wyeth Corp Anticuerpos antagonistas contra el factor 8 de crecimiento y diferenciacion y usos en el tratamiento de esclerosis lateral amiotrofica y otros trastornos relacionados con el factor 8 de crecimiento y diferenciacion.
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
UA98308C2 (en) 2006-09-05 2012-05-10 Эли Лилли Энд Компани Anti-myostatin antibody
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety

Similar Documents

Publication Publication Date Title
JP2012512641A5 (cg-RX-API-DMAC7.html)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP2018108081A5 (cg-RX-API-DMAC7.html)
JP2012530496A5 (cg-RX-API-DMAC7.html)
JP2020079252A5 (cg-RX-API-DMAC7.html)
JP2012504955A5 (cg-RX-API-DMAC7.html)
JP2022079549A5 (cg-RX-API-DMAC7.html)
JP2018521638A5 (cg-RX-API-DMAC7.html)
JP2009511579A5 (cg-RX-API-DMAC7.html)
JP2015504306A5 (cg-RX-API-DMAC7.html)
JP2010524435A5 (cg-RX-API-DMAC7.html)
JP2023071956A5 (cg-RX-API-DMAC7.html)
JP2014503209A5 (cg-RX-API-DMAC7.html)
JP2010534478A5 (cg-RX-API-DMAC7.html)
JP2011528901A5 (cg-RX-API-DMAC7.html)
JP2019522961A5 (cg-RX-API-DMAC7.html)
JP2011518886A5 (cg-RX-API-DMAC7.html)
JP2015524790A5 (cg-RX-API-DMAC7.html)
JP2011528902A5 (cg-RX-API-DMAC7.html)
WO2017080850A1 (en) Improved serum albumin-binding immunoglobulin variable domains
JP2014534242A5 (cg-RX-API-DMAC7.html)
JP2019501883A5 (cg-RX-API-DMAC7.html)
JP2018505177A5 (cg-RX-API-DMAC7.html)
JP2010500876A5 (cg-RX-API-DMAC7.html)
JP2010516229A5 (cg-RX-API-DMAC7.html)